Compare NATH & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATH | KMDA |
|---|---|---|
| Founded | 1916 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.9M | 460.3M |
| IPO Year | 1996 | 2013 |
| Metric | NATH | KMDA |
|---|---|---|
| Price | $97.81 | $8.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 19.0K | ★ 130.9K |
| Earning Date | 06-09-2026 | 05-13-2026 |
| Dividend Yield | 1.99% | ★ 3.08% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $104,201,000.00 | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | $45.72 | ★ $24.59 |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $88.67 | $6.50 |
| 52 Week High | $113.59 | $9.35 |
| Indicator | NATH | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 71.93 |
| Support Level | $97.73 | $8.38 |
| Resistance Level | $101.80 | $8.55 |
| Average True Range (ATR) | 0.80 | 0.24 |
| MACD | 0.17 | 0.14 |
| Stochastic Oscillator | 65.49 | 91.62 |
Nathan's Famous Inc is a branded licensor, wholesaler and retailer of products marketed under its brand. Its products are currently marketed for sale in thousands of locations, including supermarkets, mass merchandisers and club stores, selected foodservice locations and its company-owned and franchised restaurants throughout the United States and in twenty foreign countries. It considers itself to be in the foodservice industry. It has three segments Branded Product Program, Product Licensing, Restaurant Operations, of which majority of revenue is from Branded Product Program which derives from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors. It generates majority of revenue from United States.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.